Novo Nordisk A/S $NVO Stock Position Reduced by Equitable Trust Co.

Equitable Trust Co. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 72.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 13,132 shares of the company’s stock after selling 34,178 shares during the quarter. Equitable Trust Co.’s holdings in Novo Nordisk A/S were worth $483,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Boston Partners purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth $310,199,000. Price T Rowe Associates Inc. MD grew its stake in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Voloridge Investment Management LLC increased its position in Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the last quarter. Bank of Montreal Can increased its position in Novo Nordisk A/S by 138.9% in the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock worth $128,514,000 after purchasing an additional 1,468,409 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $59,882,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy access continues to expand, and a recent U.K. approval has added to optimism around demand for its GLP-1 franchise, supporting the stock’s recent rebound. Article Title
• Positive Sentiment: The company launched Awiqli, the world’s first once-weekly basal insulin, in India, a move that could strengthen Novo Nordisk’s diabetes footprint in a large and fast-growing market. Article Title
• Positive Sentiment: Analysts and commentators continue to argue that the stock still has a long-term bull case, with some saying the decline from highs has made the valuation more attractive relative to the company’s growth prospects. Article Title
• Neutral Sentiment: Several articles note that investors are simply watching Novo Nordisk more closely, suggesting heightened interest rather than a single new fundamental catalyst. Article Title
• Neutral Sentiment: Coverage around a Wegovy label update and broader GLP-1 enthusiasm is keeping the name in focus, but the market appears to be balancing this against the risk that competition and earnings pressure could limit upside. Article Title
• Negative Sentiment: Recent commentary also highlights rising competition in the obesity and diabetes drug markets, which could pressure Novo Nordisk’s growth and margins over time. Article Title
• Negative Sentiment: One recent market note said NVO has been slipping relative to the broader market, reflecting some near-term profit taking after the stock’s strong run. Article Title

Novo Nordisk A/S Stock Up 1.2%

Shares of NYSE NVO traded up $0.61 during mid-day trading on Friday, reaching $49.49. 6,314,361 shares of the company traded hands, compared to its average volume of 10,696,942. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market cap of $220.96 billion, a PE ratio of 11.62, a price-to-earnings-growth ratio of 4.51 and a beta of 0.77. The company’s fifty day moving average is $45.57 and its two-hundred day moving average is $45.87. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. On average, analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NVO shares. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price for the company. Finally, Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Five investment analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.